This is a Phase I study of the farnesyltransferase inhibitor, L-778,123 with radiotherapy in patients with lung cancer, head and neck cancer, and pancreatic cancer. Hypothesis is the administration of L-778, 123 for two two week periods in combination with standard radiotherapy at a dose that achieves steady state plasma concentrations of at least 2.0 uM will be generally safe and well tolerated in patients with locally advanced malignancies. The objectives of the study are: Primary: (1) Evaluate the safety and tolerability of L-778,123 including determination of the maximally tolerated dose (MTD), when administered for weeks 1, 2, 4, and 5 of radiotherapy for pancreatic cancer. (2) Define the Recommended Phase II Dose (RPTD) when L-778,123 is administered for Weeks 1 to 5 of radiotherapy for pancreatic cancer. Secondary: (1) Evaluate the safety and tolerability of L-778,123 including determination of the maximally tolerated dose (MTD), when administered for weeks 1, 2, 4, and 5 of radiotherapy for head and neck or non-small cell lung cancer. (2) Define the Recommended Phase II Dose (RPTD) when L-778,123 is administered for Weeks 1 to 5 of radiotherapy for head and neck or non-small lung cancer. (3) Evaluate radiologic or tumor marker responses to treatment with L-778,123. (4) Evaluate the relationship between ras mutations and response to treatment with L-778,123. (5) Evaluate the relationship between plasma drug levels and farnesylation assay results.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000040-40
Application #
6414405
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1974-10-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
40
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Khalili, Mandana; Shuhart, Margaret C; Lombardero, Manuel et al. (2018) Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care 41:1251-1259
Thomas, Bernadette; Matsushita, Kunihiro; Abate, Kalkidan Hassen et al. (2017) Global Cardiovascular and Renal Outcomes of Reduced GFR. J Am Soc Nephrol 28:2167-2179
Ojiro, Keisuke; Qu, Xiaowang; Cho, Hyosun et al. (2017) Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. J Virol 91:
Di Bisceglie, A M; Lombardero, M; Teckman, J et al. (2017) Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat 24:320-329
Lok, A S; Ganova-Raeva, L; Cloonan, Y et al. (2017) Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat 24:1032-1042
Leonard, Mary B; Shults, Justine; Long, Jin et al. (2016) Effect of Low-Magnitude Mechanical Stimuli on Bone Density and Structure in Pediatric Crohn's Disease: A Randomized Placebo-Controlled Trial. J Bone Miner Res 31:1177-88
Ricordi, Camillo; Goldstein, Julia S; Balamurugan, A N et al. (2016) National Institutes of Health-Sponsored Clinical Islet Transplantation Consortium Phase 3 Trial: Manufacture of a Complex Cellular Product at Eight Processing Facilities. Diabetes 65:3418-3428
Evon, Donna M; Wahed, Abdus S; Johnson, Geoffrey et al. (2016) Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). Dig Dis Sci 61:1186-96
Park, Jang-June; Wong, David K; Wahed, Abdus S et al. (2016) Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology 150:684-695.e5
Hering, Bernhard J; Clarke, William R; Bridges, Nancy D et al. (2016) Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care 39:1230-40

Showing the most recent 10 out of 423 publications